Highlights,Eli Lilly achieved a 20.4% revenue growth year-over-year in Q3.,Earnings per share (EPS) fell below expectations ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3%, and ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Kyverna Therapeutics appoints Naji Gehchan as CMO to advance KYV-101, its CD19-directed CAR-T therapy for autoimmune diseases ...

Headlines,Eli Lilly Shares Experience a Decline,Key Analyst Activity and Ratings for LLY,What's Next for Eli Lilly's ...

The sophomore was the 2024 ISL Men’s varsity champion, an ISL All-League selection, and the ISL’s most valuable performer.

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...